Skip to main content

Science
Products
Stories
Newsroom
About

Investors Media Careers Partners

Careers
Investors

Changed

Changed

How can we help you?

0 search results for

Suggestions within Pfizer.com

Press Release Archive

Press Releases

Year

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

Month

January

February

March

April

May

June

July

August

September

October

November

December

View 12

View 24

View 48

Categories

Corporate
Financial
Prescription Medicines
Research and Pipeline
Social Responsibility
Vaccines

Keywords

All Keywords

Careers
Covid-19
Finance
Investments
Leadership
Medicines
Partnerships
Research
Responsibility
Vaccines

September 2024

09.14.2024
- Research and Pipeline
- Research
Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
09.14.2024
- Prescription Medicines
- Research
Pfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
09.11.2024
- Research and Pipeline
- Research
Pfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024
09.03.2024
- Corporate
- Partnerships
Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

August 2024

08.28.2024
- Financial
- Finance
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
08.27.2024
Pfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare
08.22.2024
- Vaccines
- Vaccines
Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine
08.16.2024
Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age
08.12.2024
- Vaccines
- Vaccines
Pfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults

July 2024

07.30.2024
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
07.25.2024
- Prescription Medicines
- Medicines
European Commission Approves Pfizer’s DURVEQTIX® (fidanacogene elaparvovec), a One-Time Gene Therapy for Adults with Hemophilia B
07.24.2024
- Research and Pipeline
- Research
Pfizer Announces Positive Topline Results From Phase 3 Study of Hemophilia A Gene Therapy Candidate

Page 2
Page 3
Current page 4
Page 5
Page 6

Media Resources & Contact Information

Media Contacts
Press Kits

Anyone may view our press releases, press statements, and press kits.

However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.

Investors
Media
Careers
Partners

Grant Seekers
Healthcare Professionals
Business to Business
Merchandise

Privacy Statement
Terms of Use
Contact Us

Glossary

© 2025 Pfizer Inc. All rights reserved

This information—including product information—is intended only for residents of the United States.

The products discussed herein may have different labeling in different countries.

Twitter
Facebook
Linked In
Instagram
Youtube